An efficacy and mechanism evaluation study of Levosimendan for the Prevention of Acute oRgan Dysfunction in Sepsis (LeoPARDS): Protocol for a randomized controlled trial

Trials

Volumn 15, Issue 1, 2014, Pages

  Orme, Robert M L ^a   Perkins, Gavin D ^b   McAuley, Daniel F ^c   Liu, Kathleen D ^d   Mason, Alexina J ^e   Morelli, Andrea ^f   Singer, Mervyn ^g   Ashby, Deborah ^e   Gordon, Anthony C ^h  

^a CHELTENHAM GENERAL HOSPITAL   (United Kingdom)

^b UNIVERSITY OF WARWICK   (United Kingdom)

^c QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e IMPERIAL COLLEGE LONDON   (United Kingdom)

^f SAPIENZA UNIVERSITY OF ROME   (Italy)

^g UNIVERSITY COLLEGE LONDON   (United Kingdom)

^h CHARING CROSS HOSPITAL   (United Kingdom)

Author keywords

Critical care; Intensive care; Levosimendan; Multiple organ failure; Randomized controlled trial; Septic; Shock

Indexed keywords

BILIRUBIN; CATECHOLAMINE; DOBUTAMINE; HYDROCORTISONE; HYPERTENSIVE FACTOR; LEVOSIMENDAN; NORADRENALIN; PLACEBO; CARDIOTONIC AGENT; HYDRAZONE DERIVATIVE; PYRIDAZINE DERIVATIVE; SIMENDAN;

ACUTE KIDNEY FAILURE; ADULT; ANTIHYPERTENSIVE THERAPY; AREA UNDER THE CURVE; ARTICLE; ARTIFICIAL VENTILATION; BILIRUBIN BLOOD LEVEL; BLOOD SAMPLING; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE SEVERITY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG METABOLISM; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; EVALUATION STUDY; FOLLOW UP; HEART OUTPUT; HIGH FREQUENCY OSCILLATION; HOSPITALIZATION; HUMAN; INCIDENCE; INTENSIVE CARE UNIT; KIDNEY FAILURE; KIDNEY FUNCTION; LENGTH OF STAY; MAJOR CLINICAL STUDY; MAXIMUM PLASMA CONCENTRATION; MEAN ARTERIAL PRESSURE; MULTICENTER STUDY; MULTIPLE ORGAN FAILURE; NEUROMUSCULAR BLOCKING; OUTCOME ASSESSMENT; OXYGEN SATURATION; PARALLEL DESIGN; PATIENT CARE; PATIENT SAFETY; PHASE 2 CLINICAL TRIAL; POSITIVE END EXPIRATORY PRESSURE; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RENAL REPLACEMENT THERAPY; SAMPLE SIZE; SEPSIS; SEPTIC SHOCK; SEQUENTIAL ORGAN FAILURE ASSESSMENT SCORE; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; TREATMENT DURATION; UNITED KINGDOM; URINALYSIS; VENOUS OXYGEN TENSION; BLOOD; BLOOD FLOW; CLINICAL TRIAL; COMPLICATION; DIAPHRAGM; DRUG EFFECTS; INTENSIVE CARE; KIDNEY; METHODOLOGY; PROCEDURES; SHOCK, SEPTIC;

ADULT; CARDIAC OUTPUT; CARDIOTONIC AGENTS; DIAPHRAGM; DOUBLE-BLIND METHOD; FOLLOW-UP STUDIES; HUMANS; HYDRAZONES; INTENSIVE CARE; KIDNEY; MULTIPLE ORGAN FAILURE; PYRIDAZINES; REGIONAL BLOOD FLOW; RESEARCH DESIGN; SHOCK, SEPTIC;

EID: 84902654712     PISSN: None     EISSN: 17456215     Source Type: Journal    
DOI: 10.1186/1745-6215-15-199     Document Type: Article

References (48)

1. Harrison DA, Welch CA, Eddleston JM. The epidemiology of severe sepsis in England, Wales and Northern Ireland, 1996 to 2004: secondary analysis of a high quality clinical database, the ICNARC Case Mix Programme Database. Crit Care 2006, 10:R42. 10.1186/cc4854, 1550902, 16542492.
2. Vincent JL, Moreno R, Takala J, Willatts S, De Mendonca A, Bruining H, Reinhart CK, Suter PM, Thijs LG. The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine. Intensive Care Med 1996, 22:707-710. 10.1007/BF01709751, 8844239.
3. Ferreira FL, Bota DP, Bross A, Melot C, Vincent JL. Serial evaluation of the SOFA score to predict outcome in critically ill patients. JAMA 2001, 286:1754-1758. 10.1001/jama.286.14.1754, 11594901.
4. Oppert M, Engel C, Brunkhorst FM, Bogatsch H, Reinhart K, Frei U, Eckardt KU, Loeffler M, John S. Acute renal failure in patients with severe sepsis and septic shock-a significant independent risk factor for mortality: results from the German Prevalence Study. Nephrol Dial Transplant 2008, 23:904-909.
5. Gheorghiade M, Teerlink JR, Mebazaa A. Pharmacology of new agents for acute heart failure syndromes. Am J Cardiol 2005, 96:68G-73G. 10.1016/j.amjcard.2005.07.023, 16181825.
6. Sorsa T, Pollesello P, Solaro RJ. The contractile apparatus as a target for drugs against heart failure: interaction of levosimendan, a calcium sensitiser, with cardiac troponin c. Mol Cell Biochem 2004, 266:87-107.
7. Papp Z, Edes I, Fruhwald S, De Hert SG, Salmenpera M, Leppikangas H, Mebazaa A, Landoni G, Grossini E, Caimmi P, Morelli A, Guarracino F, Schwinger RH, Meyer S, Algotsson L, Wikstrom BG, Jorgensen K, Filippatos G, Parissis JT, Gonzalez MJ, Parkhomenko A, Yilmaz MB, Kivikko M, Pollesello P, Follath F. Levosimendan: Molecular mechanisms and clinical implications Consensus of experts on the mechanisms of action of levosimendan. Int J Cardiol 2012, 159:82-87. 10.1016/j.ijcard.2011.07.022, 21784540.
8. Hasslacher J, Bijuklic K, Bertocchi C, Kountchev J, Bellmann R, Dunzendorfer S, Joannidis M. Levosimendan inhibits release of reactive oxygen species in polymorphonuclear leukocytes in vitro and in patients with acute heart failure and septic shock: a prospective observational study. Crit Care 2011, 15:R166. 10.1186/cc10307, 3387603, 21749676.
9. Kankaanranta H, Zhang X, Tumelius R, Ruotsalainen M, Haikala H, Nissinen E, Moilanen E. Antieosinophilic activity of simendans. J Pharmacol Exp Ther 2007, 323:31-38.
10. Delaney A, Bradford C, McCaffrey J, Bagshaw SM, Lee R. Levosimendan for the treatment of acute severe heart failure: a meta-analysis of randomised controlled trials. Int J Cardiol 2010, 138:281-289. 10.1016/j.ijcard.2008.08.020, 18817994.
11. Vieillard-Baron A, Caille V, Charron C, Belliard G, Page B, Jardin F. Actual incidence of global left ventricular hypokinesia in adult septic shock. Crit Care Med 2008, 36:1701-1706. 10.1097/CCM.0b013e318174db05, 18496368.
12. Charpentier J, Luyt CE, Fulla Y, Vinsonneau C, Cariou A, Grabar S, Dhainaut JF, Mira JP, Chiche JD. Brain natriuretic peptide: A marker of myocardial dysfunction and prognosis during severe sepsis. Crit Care Med 2004, 32:660-665. 10.1097/01.CCM.0000114827.93410.D8, 15090944.
13. Rudiger A, Singer M. Mechanisms of sepsis-induced cardiac dysfunction. Crit Care Med 2008, 35:1599-1608.
14. Singer M. Catecholamine treatment for septic shock - equally good or bad?. Lancet 2007, 370:636-637. 10.1016/S0140-6736(07)61317-8, 17719998.
15. Annane D, Vignon P, Renault A, Bollaert P-E, Charpentier C, Martin C, Troché G, Ricard J-D, Nitenberg G, Papazian L, Azoulay E, Bellissant E, . CATS Study Group Norepinephrine plus dobutamine versus epinephrine alone for management of septic shock: a randomised trial. Lancet 2007, 370:676-684. 10.1016/S0140-6736(07)61344-0, 17720019, CATS Study Group.
16. Dunser MW, Ruokonen E, Pettila V, Ulmer H, Torgersen C, Schmittinger CA, Jakob S, Takala J. Association of arterial blood pressure and vasopressor load with septic shock mortality: a post hoc analysis of a multicenter trial. Crit Care 2009, 13:R181. 10.1186/cc8167, 2811945, 19917106.
17. Boldt J, Menges T, Kuhn D, Diridis C, Hempelmann G. Alterations in circulating vasoactive substances in the critically ill-a comparison between survivors and non-survivors. Intensive Care Med 1995, 21:218-225. 10.1007/BF01701475, 7790607.
18. Morelli A, Ertmer C, Westphal M, Rehberg S, Kampmeier T, Ligges S, Orecchioni A, D'Egidio A, D'Ippoliti F, Raffone C, Venditti M, Guarracino F, Girardis M, Tritapepe L, Pietropaoli P, Mebazaa A, Singer M. Effect of heart rate control with esmolol on hemodynamic and clinical outcomes in patients with septic shock: a randomized clinical trial. JAMA 2013, 310:1683-1691. 10.1001/jama.2013.278477, 24108526.
19. Zager RA, Johnson AC, Lund S, Hanson SY, Abrass CK. Levosimendan protects against experimental endotoxemic acute renal failure. Am J Physiol Renal Physiol 2006, 290:F1453-F1462. 10.1152/ajprenal.00485.2005, 16418300.
20. Rehberg S, Ertmer C, Vincent J-L, Spiegel H-U, Köhler G, Erren M, Lange M, Morelli A, Seisel J, Su F, Van Aken H, Traber DL, Westphal M. Effects of combined arginine vasopressin and levosimendan on organ function in ovine septic shock. Crit Care Med 2010, 38:2016-2023.
21. Garcia-Septien J, Lorente JA, Delgado MA, de Paula M, Nin N, Moscoso A, Sanchez-Ferrer A, Perez-Vizcaino F, Esteban A. Levosimendan increases portal blood flow and attenuates intestinal intramucosal acidosis in experimental septic shock. Shock 2010, 34:275-280. 10.1097/SHK.0b013e3181cd8c5b, 19997054.
22. Fries M, Ince C, Rossaint R, Bleilevens C, Bickenbach J, Rex S, Mik EG. Levosimendan but not norepinephrine improves microvascular oxygenation during experimental septic shock. Crit Care Med 2008, 36:1886-1891. 10.1097/CCM.0b013e31817cede9, 18496356.
23. Dubin A, Murias G, Sottile JP, Pozo MO, Baran M, Edul VS, Canales HS, Etcheverry G, Maskin B, Estenssoro E. Effects of levosimendan and dobutamine in experimental acute endotoxemia: a preliminary controlled study. Intensive Care Med 2007, 33:485-494. 10.1007/s00134-006-0519-5, 17262190.
24. Noto A, Giacomini M, Palandi A, Stabile L, Reali-Forster C, Iapichino G. Levosimendan in septic cardiac failure. Intensive Care Med 2005, 31:164-165. 10.1007/s00134-004-2502-3, 15580334.
25. Matejovic M, Krouzecky A, Radej J, Novak I. Successful reversal of resistent hypodynamic septic shock with levosimendan. Acta Anaesthesiol Scand 2005, 49:127-128.
26. Ramaswamykanive H, Bihari D, Solano TR. Myocardial depression associated with pneumococcal septic shock reversed by levosimendan. Anaesth Intensive Care 2007, 35:409-413.
27. Powell BP, De Keulenaer BL. Levosimendan in septic shock: a case series. Br J Anaesth 2007, 99:447-448. 10.1093/bja/aem225, 17702832.
28. Morelli A, De Castro S, Teboul J-L, Singer M, Ronco M, Conti G, De Luca L, Di Angelantonia E, Orecchioni A, Pandian NG, Pietropaoli P. Effects of levosimendan on systemic and regional hemodynamics in septic myocardial depression. Intensive Care Med 2005, 31:638-644. 10.1007/s00134-005-2619-z, 15812624.
29. Morelli A, Teboul J-L, Maggiore SM, Vieillard-Baron A, Rocco M, Conti G, De Gaetano A, Picchini U, Orecchioni A, Carbone I, Tritapepe L, Pietropaoli P, Westphal M. Effects of levosimendan on right ventricular afterload in patients with acute respiratory distress syndrome: a pilot study. Crit Care Med 2006, 34:2287-2293. 10.1097/01.CCM.0000230244.17174.4F, 16791109.
30. Morelli A, Donati A, Ertmer C, Rehberg S, Lange M, Orecchioni A, Cecchini V, Landoni G, Pelaia P, Pietropaoli P, Van Aken H, Teboul JL, Ince C, Westphal M. Levosimendan for resuscitating the microcirculation in patients with septic shock: a randomized controlled study. Crit Care 2010, 14:R232. 10.1186/cc9387, 3219978, 21182783.
31. Alhashemi JA, Alotaibi QA, Abdullah GM, Shalabi SA. Levosimendan vs dobutamine in septic shock. J Crit Care 2009, 24:e14-e15. 10.1016/j.jcrc.2009.06.006, 19664518.
32. Vaitsis J, Michalpoulou H, Thomopoulos C. Use of levosimendan in myocardial dysfunction due to sepsis. Crit Care 2009, 13:165. 10.1186/cc7935, 2750139, 19664168.
33. Memis D, Inal MT, Sut N. The effects of levosimendan vs dobutamine added to dopamine on liver functions assessed with noninvasive liver function monitoring in patients with septic shock. J Crit Care 2012, 27(318):e311-e316.
34. Morelli A, Ertmer C, Rehberg S. Effects of levosimendan on renal function in septic shock: a case control study. Crit Care 2009, 13:170. 10.1186/cc7970, 2750168, 19678905.
35. Pinto BB, Rehberg S, Ertmer C, Westphal M. Role of levosimendan in sepsis and septic shock. Curr Opin Anaesthesiol 2008, 21:168-177. 10.1097/ACO.0b013e3282f43c56, 18443483.
36. Reinhart K, Brunkhorst FM, Bone HG, Bardutzky J, Dempfle CE, Forst H, Gastmeier P, Gerlach H, Grundling M, John S, Kern W, Kreymann G, Kruger W, Kujath P, Marggraf G, Martin J, Mayer K, Meier-Hellmann A, Oppert M, Putensen C, Quintel M, Ragaller M, Rossaint R, Seifert H, Spies C, Stuber F, Weiler N, Weimann A, Werdan K, Welte T. Prevention, diagnosis, therapy and follow-up care of sepsis: 1st revision of S-2k guidelines of the German Sepsis Society (Deutsche Sepsis-Gesellschaft e.V. (DSG)) and the German Interdisciplinary Association of Intensive Care and Emergency Medicine (Deutsche Interdisziplinare Vereinigung fur Intensiv- und Notfallmedizin (DIVI)). Ger Med Sci 2010, 8:Doc14. 2899863, 20628653.
37. Harvey SE, Elbourne D, Ashcroft J, Jones CM, Rowan K. Informed consent in clinical trials in critical care: experience from the PAC-Man Study. Intensive Care Med 2006, 32:2020-2025. 10.1007/s00134-006-0358-4, 17019555.
38. Gordon AC, Wang N, Walley KR, Ashby D, Russell JA. The cardiopulmonary effects of vasopressin compared with norepinephrine in septic shock. Chest 2012, 142:593-605. 10.1378/chest.11-2604, 22518026.
39. Doorduin J, Sinderby CA, Beck J, Stegeman DF, van Hees HW, van der Hoeven JG, Heunks LM. The calcium sensitizer levosimendan improves human diaphragm function. Am J Resp Crit Care Med 2012, 185:90-95. 10.1164/rccm.201107-1268OC, 21960535.
40. Mehta RL, Kellum JA, Shah SV, Molitoris BA, Ronco C, Warnock DG, Levin A. Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury. Crit Care 2007, 11:R31. 10.1186/cc5713, 2206446, 17331245.
41. Gordon AC, Russell JA, Walley KR, Singer J, Ayers D, Storms MM, Holmes CL, Hebert PC, Cooper DJ, Mehta S, Granton JT, Cook DJ, Presneill JJ. The effects of vasopressin on acute kidney injury in septic shock. Intensive Care Med 2010, 36:83-91. 10.1007/s00134-009-1687-x, 19841897.
42. Gordon AC, Mason AJ, Perkins GD, Stotz M, Terblanche M, Ashby DA, Brett SJ. The interaction of vasopressin and corticosteroids in septic shock: a pilot randomized controlled trial. Crit Care Med 2014, 42:1325-1333. 10.1097/CCM.0000000000000212, 24557425.
43. Moreno R, Sprung CL, Annane D, Chevret S, Briegel J, Keh D, Singer M, Weiss YG, Payen D, Cuthbertson BH, Vincent JL. Time course of organ failure in patients with septic shock treated with hydrocortisone: results of the Corticus study. Intensive Care Med 2011, 37:1765-1772. 10.1007/s00134-011-2334-x, 21847649.
44. de Geus HR, Bakker J, Lesaffre EM, le Noble JL. Neutrophil gelatinase-associated lipocalin at ICU admission predicts for acute kidney injury in adult patients. Am J Resp Crit Care Med 2011, 183:907-914. 10.1164/rccm.200908-1214OC, 20935115.
45. Kashani K, Al-Khafaji A, Ardiles T, Artigas A, Bagshaw SM, Bell M, Bihorac A, Birkhahn R, Cely CM, Chawla LS, Davison DL, Feldkamp T, Forni LG, Gong MN, Gunnerson KJ, Haase M, Hackett J, Honore PM, Hoste EA, Joannes-Boyau O, Joannidis M, Kim P, Koyner JL, Laskowitz DT, Lissauer ME, Marx G, McCullough PA, Mullaney S, Ostermann M, Rimmele T, et al. Discovery and validation of cell cycle arrest biomarkers in human acute kidney injury. Crit Care 2013, 17:R25. 10.1186/cc12503, 4057242, 23388612.
46. Post F, Weilemann LS, Messow CM, Sinning C, Munzel T. B-type natriuretic peptide as a marker for sepsis-induced myocardial depression in intensive care patients. Crit Care Med 2008, 36:3030-3037. 10.1097/CCM.0b013e31818b9153, 18824903.
47. Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H, Opal SM, Sevransky JE, Sprung CL, Douglas IS, Jaeschke R, Osborn TM, Nunnally ME, Townsend SR, Reinhart K, Kleinpell RM, Angus DC, Deutschman CS, Machado FR, Rubenfeld GD, Webb S, Beale RJ, Vincent JL, Moreno R, . the Surviving Sepsis Campaign Guidelines Committee including the Pediatric Subgroup Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock, 2012. Intensive Care Med 2013, 39:165-228. 10.1007/s00134-012-2769-8, 23361625, the Surviving Sepsis Campaign Guidelines Committee including the Pediatric Subgroup.
48. Rabindranath KS, Adams J, MacLeod AM, Muirhead N. Intermittent versus continuous renal replacement therapy for acute renal failure in adults. Cochrane Database Syst Rev 2007, (3):Article Number: CD003773. doi:10.1002/14651858.CD003773.pub3.